Eliem Financial Statements From 2010 to 2024
| ELYMDelisted Stock | USD 3.00 0.09 2.91% |
Check Eliem Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eliem Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Eliem financial statements analysis is a perfect complement when working with Eliem Therapeutics Valuation or Volatility modules.
Eliem |
Eliem Therapeutics Company Shares Outstanding Analysis
Eliem Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Eliem Therapeutics Shares Outstanding | 67.06 M |
Most of Eliem Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eliem Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Eliem Therapeutics has 67.06 M of shares currently outstending. This is 62.85% lower than that of the Biotechnology sector and 37.24% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 88.27% higher than that of the company.
Eliem Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eliem Therapeutics's current stock value. Our valuation model uses many indicators to compare Eliem Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eliem Therapeutics competition to find correlations between indicators driving Eliem Therapeutics's intrinsic value. More Info.Eliem Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Eliem Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Eliem Therapeutics Financial Statements
Eliem Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Eliem Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington. Eliem Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Eliem Therapeutics Correlation against competitors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |